Bacterial Infections  >>  Ilaris (canakinumab)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ilaris (canakinumab) / Novartis
NCT01088880 / 2015-003527-57: Efficacy and Safety of Canakinumab in Patients With Colchicine Resistant Familial Mediterranean Fever

Checkmark For colchicine resistant familial mediterranean fever
Jun 2014 - Jun 2014: For colchicine resistant familial mediterranean fever
Checkmark P2 data - ACR/ARHP 2012
Sep 2012 - Sep 2012: P2 data - ACR/ARHP 2012
Completed
2
10
RoW
Canakinumab
Novartis Pharmaceuticals
Familial Mediterranean Fever
08/11
08/11
CONTROL FMF, NCT01148797 / 2015-003522-13: Evaluate the Safety and Efficacy of Canakinumab in Pediatric Patients With Colchicine Intolerant or Colchicine Resistant Familial Mediterranean Fever (FMF)

Checkmark For colchicine resistant familial mediterranean fever
Jun 2014 - Jun 2014: For colchicine resistant familial mediterranean fever
Checkmark Resistant familial mediterranean Fever
Mar 2014 - Mar 2014: Resistant familial mediterranean Fever
Checkmark EULAR 2013: Familial mediterranean fever
More
Completed
2
15
RoW
Canakinumab
Novartis Pharmaceuticals
Colchicine Resistant/Intolerant Familial Mediterranean Fever
02/12
 

Download Options